INAB - Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan in8bio.com

IN8bio, Inc. (INAB) is developing cellular therapies for oncohematology, facing typical biotech risks regarding capital burn and clinical trial uncertainty. Diagnostic efficiency is driven by deep automation of laboratory sample analysis. The visualization of EV/EBITDA price dynamics is 0.00. Operational stability is maintained by outsourcing all research to external CRO contractors, which minimizes internal production disruptions.

INAB IN8bio, Inc: Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan ing interval 23.11.2025 - 12.11.2026

in8bio.com - rincian analitis lan metrik utama (INAB)

- rega saiki lan proyeksi nilai saham:

Rega saham IN8bio, Inc|INAB - Bagan rega target

- statistik kapitalisasi pasar:

Nilai pasar IN8bio Inc|INAB - Nilai Total Perusahaan

- indikator nilai buku ekuitas:

Aset Bersih saben Siji Saham IN8bio|INAB - Ekuitas Perusahaan|Rasio Nilai Pasar marang Nilai Buku in8bio.com|INAB - Aset Perusahaan

- rincian struktur utang lan likuiditas bisnis:

Total Utang marang Modal IN8bio, Inc.|INAB - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal IN8bio|INAB - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku IN8bio Inc|INAB - Tanggungan utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan IN8bio|Likuiditas cepet in8bio.com

- data bathi bisnis lan rasio investasi:

INAB - Bathi resik|Prakiraan bathi perusahaan IN8bio, Inc.|INAB - Rasio rega marang bathi|Rasio prakiraan rega marang bathi IN8bio, Inc.|INAB - Pangali rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan IN8bio Inc|INAB - Bathi operasional EBITDA|Bathi resik saben saham sajrone patang kuartal pungkasan IN8bio|INAB - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan in8bio.com|INAB - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep IN8bio, Inc.

Analisis komprehensif perusahaan:INAB (IN8bio, Inc)

By outsourcing production and clinical trials, IN8bio, Inc. (INAB) minimizes capital expenditures, which directly impacts the profit calculation base. This metric compares the total enterprise value, including debt, with earnings before interest, taxes, depreciation, and amortization, determining the payback period for assets. By analyzing the EV/EBITDA ratio in a historical context, an investor can distinguish fundamental undervaluation from a "value trap" during a decline in operational efficiency.

Analisis pesaing IN8bio, Inc.